NASDAQ:OTLK Oncobiologics Q4 2024 Earnings Report $0.23 -0.02 (-8.36%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncobiologics EPS ResultsActual EPS-$0.77Consensus EPS -$0.83Beat/MissBeat by +$0.06One Year Ago EPSN/AOncobiologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncobiologics Announcement DetailsQuarterQ4 2024Date12/27/2024TimeBefore Market OpensConference Call DateFriday, December 27, 2024Conference Call Time7:00AM ETUpcoming EarningsOncobiologics' Q2 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Oncobiologics Earnings HeadlinesOncobiologics (OTLK) Projected to Post Earnings on ThursdayMay 7, 2026 | americanbankingnews.comOncobiologics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Hold" from AnalystsMay 7, 2026 | americanbankingnews.comIs $24 trillion about to move?Bloomberg reports that S-P Dow Jones Indices is considering rule changes that could fast-track SpaceX into the S-P 500 immediately after its IPO - and roughly $24 trillion in index-tracking funds would be forced to buy shares the moment it joins. At a $1.5 trillion valuation, SpaceX would enter larger than Tesla, potentially making this the biggest IPO in Wall Street history. Dr. Mark Skousen has identified a free ticker that offers pre-IPO exposure before the index funds move in.May 12 at 1:00 AM | The Oxford Club (Ad)Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingApril 23, 2026 | globenewswire.comOutlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 22, 2026 | globenewswire.comOutlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVAâ„¢ (bevacizumab-vikg)April 21, 2026 | globenewswire.comSee More Oncobiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncobiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your email. Email Address About OncobiologicsOncobiologics (NASDAQ:OTLK) is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation. Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets. The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.View Oncobiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingShake Shack Stock Gets Shaken After Earnings MissRocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?MP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount Deepens Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
